[1] Pritchett RF, Hayward SD, Kieff ED. DNA of Epstein-Barr virus.I.comparative studies of the DNA of Epstein-Barr virus from HR-1 and B95-8 cells: size, structure, and relatedness.J Virol,1975,15(3):556-559.
[2] Dunmire SK, Verghese PS, Balfour HH Jr. Primary Epstein-Barr virus infection. J Clin Virol,2018,102:84-92.
[3] Balfour HH Jr,Sifakis F,Sliman JA,et al.Age-specific prevalence of Epstein-Barr virus infection among individuals aged 6-19 years in the United States and factors affecting its acquisition.J Infect Dis,2013,208(8):1286-1293.
[4] Gares V,Panico L,Castagne R,et al.The role of the early social environment on Epstein Barr virus infection: a prospective observational design using the millennium cohort study.Epidemiol Infect,2017,145(16):3405-3412.
[5] Shi T, Huang L, Chen Z, et al. Characteristics of primary Epstein-Barr virus infection disease spectrum and its reactivation in children, in Suzhou, China. J Med Virol, 2021,93(8):5048-5057.
[6] Cai F, Gao H, Ye Q.Seroprevalence of Epstein-Barr virus infection in children during the COVID-19 pandemic in Zhejiang,China.Front Pediatr,2023,11:1064330.
[7] Cai X, Ebell MH, Haines L.Accuracy of signs, symptoms, and hematologic parameters for the diagnosis of infectious mononucleosis: a systematic review and Meta-analysis.J Am Board Fam Med,2021,34(6):1141-1156.
[8] Ye Z,Chen L,Zhong H,et al.Epidemiology and clinical characteristics of Epstein-Barr virus infection among children in Shanghai,China,2017-2022.Front Cell Infect Microbiol,2023,13:1139068.
[9] Shi T,Huang L,Tian J.Prevalence of Epstein-Barr viral DNA among children at a single hospital in Suzhou, China.J Pediatr (Rio J),2022,98(2):142-146.
[10] Kuri A,Jacobs BM,Vickaryous N,et al.Epidemiology of Epstein-Barr virus infection and infectious mononucleosis in the United Kingdom.BMC Public Health,2020,20(1):912.
[11] Gao LW,Xie ZD,Liu YY,et al.Epidemiologic and clinical characteristics of infectious mononucleosis associated with Epstein-Barr virus infection in children in Beijing,China.World J Pediatr,2011,7(1):45-49.
[12] Bradham CA,Plümpe J,Manns MP,et al.Mechanisms of hepatic toxicity.I. TNF-induced liver injury.Am J Physiol,1998,275(3):387-392.
[13] Kondo T, Suda T, Fukuyama H, et al. Essential roles of the fas ligand in the development of hepatitis. Nat Med, 1997,3(4):409-413.
[14] Kimura H, Nagasaka T, Hoshino Y, et al. Severe hepatitis caused by Epstein-Barr virus without infection of hepatocytes. Hum Pathol, 2001,32(7):757-762.
[15] Crum NF. Epstein Barr virus hepatitis: case series and review. South Med J, 2006,99(5):544-547.
[16] Yang SI, Geong JH, Kim JY. Clinical characteristics of primary Epstein Barr virus hepatitis with elevation of alkaline phosphatase and γ-glutamyltransferase in children. Yonsei Med J, 2014,55(1):107-112.
[17] 中华医学会儿科学分会感染学组, 全国儿童EB病毒感染协作组. 儿童EB病毒感染相关疾病的诊断和治疗原则专家共识.中华儿科杂志,2021,59(11):905-911.
[18] Simpson L, Sutherland E, Wilkinson D, et al. Infectious mononucleosis - should we routinely assess liver function in acute presentation and follow up? J Laryngol Otol, 2023,137(3):319-322.
[19] 王云花,马丹,马利敏等.双环醇治疗EB病毒肝炎儿童疗效分析.实用肝脏病杂志,2020,23(3):451-452.
[20] Wang Y, Luo Y, Tang G, et al. HLA-DR expression level in CD8(+) T cells correlates with the severity of children with acute infectious mononucleosis. Front Immunol, 2021,12:753290.
[21] Kimura H, Cohen JI.Chronic active Epstein-Barr virus disease.Front Immunol, 2017,8:1867.
[22] Chen S, Wei A, Ma H, et al. Clinical features and prognostic factors of children with chronic active Epstein-Barr virus infection: a retrospective analysis of a single center.J Pediatr,2021,238:268-274,e2.
[23] Sawada A, Inoue M, Kawa K. How we treat chronic active Epstein-Barr virus infection.Int J Hematol,2017,105(4):406-418.
[24] Nakajima K,Hiejima E,Nihira H,et al.Case report:a case of Epstein-Barr virus-associated acute liver failure requiring hematopoietic cell transplantation after emergent liver transplantation.Front Immunol, 2022,13:825806.
[25] Yamamoto M, Sato M, Onishi Y, et al. Registry data analysis of hematopoietic stem cell transplantation on systemic chronic active Epstein-Barr virus infection patients in Japan. Am J Hematol, 2022,97(6):780-790.
[26] 肖莉, 管贤敏, 孟岩, 等.217例噬血细胞性淋巴组织细胞增生症患儿的临床及实验室检查特点分析. 中华血液学杂志,2014,35(7): 628-632.
[27] Jordan MB, Allen CE, Greenberg J, et al. Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO). Pediatr Blood Cancer, 2019,66(11):e27929.
[28] 卢根, 谢正德, 申昆玲, 等.儿童EB病毒相关性噬血细胞淋巴组织细胞增生症的临床特征和预后危险因素分析.中华儿科杂志,2010,48(2):121-126.
[29] Henter JI, Samuelsson-Horne A, Aricò M, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation.Blood,2002,100(7):2367-2373.
[30] Kogawa K,Sato H,Asano T,et al.Prognostic factors of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children:report of the Japan histiocytosis study Group.Pediatr Blood Cancer,2014,61(7):1257-1262. |